CANCER PREVENTION AND CONTROL PROGRAM Kerri Winters-Stone, Ph.D., and Pepper Schedin, Ph.D., Program Co-Leaders ABSTRACT Cancer is the most common cause of death in Oregonians, making cancer prevention and control key statewide objectives. Research within the Cancer Prevention and Control (CPC) Program is focused on reducing cancer incidence, morbidity and mortality through innovative approaches that translate knowledge from the bench to at- risk populations and communities. The program strategically focuses on three thematic areas that have high impact across the cancer continuum: 1) prevention and risk reduction, 2) early detection and screening, and 3) cancer survivorship to address health issues from diagnosis to end of life. Researchers in the CPC Program have uncovered novel mechanisms of increased cancer risk including genetic predisposition for UV-induced oxidative stress in melanocytes, nutrient regulation of histone deacetylase activity in prostate and breast, and COX-2- dependent stromal remodeling in breast, developed culturally-tailored education programs to promote cancer screening uptake, have led in the development of national screening recommendations and best practices within the areas of breast, melanoma, colon and lung cancer, defined key mechanisms responsible for debilitating symptoms in cancer survivors such as cachexia, fatigue, and decreased cognition, and have led studies that apply exercise as a countermeasure to reduce inflammation and restore energy balance and musculoskeletal health that are now part of national guidelines. The program is co-led by Kerri Winters-Stone, PhD, and Pepper Schedin, PhD, two senior scientists with complimentary expertise in population-based survivorship research and laboratory- based preclinical chemoprevention, respectively. The 31 members are drawn from nine departments in the School of Medicine and the School of Nursing. Annual total cost funding as of January 2016 amounted to $5,605,762, of which $3,109,502 was from the NCI and $4,718,559 was peer-reviewed. The discoveries made in this program have resulted in 247 publications, of which 30% are intra-programmatic, 12.6% inter-programmatic, and 62.8% inter-institutional collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-21
Application #
9733150
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6

Showing the most recent 10 out of 277 publications